Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI

Mereo BioPharma Group (MREO) and its partner Ultragenyx Pharmaceutical (RARE) will continue their Phase 3 ORBIT study as planned, with final analysis anticipated by the end of 2025. This update provides a clear timeline for a significant clinical trial milestone, relevant for investors tracking the progress of these biopharmaceutical companies.

Analysis

Mereo BioPharma Group (MREO) and its partner Ultragenyx Pharmaceutical (RARE) have reaffirmed the continuation of their Phase 3 ORBIT study, establishing a clear timeline with final analysis expected by the end of 2025. This confirmation indicates the trial is proceeding as planned without any apparent setbacks that would necessitate an early halt. For both companies, this sets a key, albeit distant, catalyst. The mildly positive sentiment signals that this is not a new breakthrough but rather a reduction of near-term uncertainty regarding the study's continuation. The primary takeaway is the establishment of a long-term value inflection point, pushing the next major data-driven event for this specific program out by more than a year.

Key Decisions for Investors

• Investors should adjust their holding period expectations for both MREO and RARE, as the next significant catalyst for the ORBIT study is now firmly set for the end of 2025.
• Consider this announcement a modest de-risking event, as it confirms the trial has not been stopped for futility or safety, but recognize that the ultimate binary risk of the final data readout remains.
• Monitor both companies for any interim updates on trial enrollment or protocol, as the extended period until the 2025 final analysis creates a long window with potentially limited news flow on this specific asset.